Study of Monitoring Exhaled NO in Symptomatic Asthmatic Adults and Children During Anti-inflammatory Treatment (eNOugh)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00388570|
Recruitment Status : Completed
First Posted : October 17, 2006
Last Update Posted : November 4, 2011
|Condition or disease||Intervention/treatment||Phase|
|Asthma||Device: The Aerocrine NIOX MINO® Airway Inflammation Monitor||Not Applicable|
Asthma is a chronic inflammatory disorder of the airways. Chronically inflamed airways are hyperresponsive; they become obstructed and airflow is limited (by bronchoconstriction, mucus plugs, and increased inflammation) when airways are exposed to various risk factors. Asthma causes recurring episodes of wheezing, breathlessness, chest tightness, and coughing particularly at night or in the early morning.
NO is an important endogenous regulatory molecule that is widely distributed throughout the body. The detection of NO in exhaled air was first reported in 1991, and, soon after it was shown that the levels NO in exhaled air are elevated in patients with asthma. There is now much evidence showing that measurement of the concentration of NO in exhaled air offers a useful non−invasive method of assessing inflammatory airway disease.
Exhaled NO is not increased during bronchospasm unless there is coexisting inflammation. Exhaled NO may have a valuable role in differentiating between the inflammatory and bronchospastic components of clinical asthma, and is also useful for guiding the therapeutic use of steroids and other anti−inflammatory agents.
A study on asthmatics and non−asthmatics subjects has shown that substantial equivalence exists between the stationary device NIOX® and the hand held device NIOX MINO® when comparing NO measurements, when similar conditions are considered and examinations are made as consistently as possible.
In a study with the stationary device NIOX®, exhaled NO was measured before and after two weeks of inhaled corticosteroid treatment in unstable steroid−naïve adult and paediatric asthmatic subjects. The result was a 50.5% mean reduction of exhaled NO. The change in exhaled NO was also compared to change in standard asthma outcome measures, asthma symptoms and spirometry.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||151 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||A Multicenter, Device Randomized, Open-label Prospective Single-cohort Study of Monitoring Exhaled NO in Symptomatic Asthmatic Adults and Children During Anti-inflammatory Treatment|
|Study Start Date :||October 2006|
|Actual Primary Completion Date :||June 2007|
|Actual Study Completion Date :||July 2007|
- The primary analysis variable will be the percent change in FENO measured with
- NIOX MINO® and NIOX® between Visit 1 to Visit 2.
- Agreement between NIOX MINO® and NIOX® will be assessed by comparing
- individual pair-wise FENO measurements from visit V1.
- The change in FENO measured with NIOX MINO following corticosteroid therapy
- in asthma will be compared with improvements in standard asthma outcome
- measures (asthma symptoms and spirometry).
- To investigate the inter-operator variability FENO measurements with
- NIOX MINO in the same subject when different operators take FENO measurements. Three operator each takes two completed measurements in the same subject in a point of care setting.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00388570
|Näsets Läkargrupp, Falsterbov. 79, SE-23651 Höllviken|
|Höllviken, Sweden, SE-23651|
|Department of General Practice & Primary Care University of Aberdeen|
|Aberdeen, United Kingdom, AB252AY|
|Study Chair:||David Price, Professor||Dept of General Practice and Primary Care, University of Aberdeen|
|Study Chair:||Sven-Erik Dahlén, Professor||Unit for Experimental Asthma and Allergy Research Division of Physiology, The National Institute of Environmental Medicine Karolinska Institutet|